Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study.

Groen HJM, van der Heijden EHFM, Klinkenberg TJ, Biesma B, Aerts J, Verhagen A, Kloosterziel C, Pieterman R, van den Borne B, Smit HJM, Hoekstra O, Schramel FMNH, van der Noort V, van Tinteren H, Smit EF, Dingemans AC; NVALT Study Group, the Netherlands.

Br J Cancer. 2019 Aug;121(5):372-377. doi: 10.1038/s41416-019-0533-3. Epub 2019 Jul 24.

PMID:
31337877
2.

Pulmonary injury associated with spray of a water-based nano-sized waterproofing product: a case study.

Scheepers PTJ, Masen-Poos L, van Rooy FGBGJ, Oerlemans A, van Daalen E, Cremers R, Lichtenbeld H, Biesma B, Sørli JB, Koponen IK, Larsen ST, Wolkoff P, Nørgaard AW.

J Occup Med Toxicol. 2017 Dec 8;12:33. doi: 10.1186/s12995-017-0180-7. eCollection 2017.

3.

Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial.

Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AMJ, Juan Vidal Ó, Palmero Sanchez R, Villa Guzmán JC, Collado Martin R, Peralta S, Insa A, Summers Y, Láng I, Horgan A, Ciardiello F, de Hosson S, Pieterman R, Groen HJM, van den Berg PM, Zielinski CC, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Kassapian M, Novello S, Torri V, Tsourti Z, Gregorc V, Smit EF; EMPHASIS-lung Collaborative Group.

J Thorac Oncol. 2017 Apr;12(4):752-762. doi: 10.1016/j.jtho.2016.12.017. Epub 2016 Dec 23.

4.

Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?

Hendriks LEL, Brouns -JWM, Amini M, Uyterlinde W, Wijsman R, Bussink J, Biesma B, Oei SB, Stigt JA, Bootsma GP, Belderbos JSA, De Ruysscher DKM, Van den Heuvel MM, Dingemans AC.

Lung Cancer. 2016 Nov;101:68-75. doi: 10.1016/j.lungcan.2016.09.008. Epub 2016 Sep 9.

5.

PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, Martinez Aguillo M, Aerts J, Govindan R, Rubio-Viqueira B, Lewanski C, Gandara D, Choy H, Mok T, Hossain A, Iscoe N, Treat J, Koustenis A, San Antonio B, Chouaki N, Vokes E.

J Clin Oncol. 2016 Mar 20;34(9):953-62. doi: 10.1200/JCO.2015.64.8824. Epub 2016 Jan 25.

PMID:
26811519
6.

A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)†.

Dingemans AM, Groen HJ, Herder GJ, Stigt JA, Smit EF, Bahce I, Burgers JA, van den Borne BE, Biesma B, Vincent A, van der Noort V, Aerts JG; NVALT study group.

Ann Oncol. 2015 Nov;26(11):2286-93. doi: 10.1093/annonc/mdv370. Epub 2015 Sep 7.

PMID:
26347109
7.

Pharmacotherapy for treatment of lung cancer in the elderly.

van Veggel BA, Biesma B, Smit EF.

Expert Opin Pharmacother. 2015 May;16(7):1021-34. doi: 10.1517/14656566.2015.1028357. Epub 2015 Mar 22. Review.

PMID:
25797389
8.

Comorbidity in Patients With Small-Cell Lung Cancer: Trends and Prognostic Impact.

Aarts MJ, Aerts JG, van den Borne BE, Biesma B, Lemmens VE, Kloover JS.

Clin Lung Cancer. 2015 Jul;16(4):282-91. doi: 10.1016/j.cllc.2014.12.003. Epub 2014 Dec 11.

PMID:
25572007
9.

Improvement in population-based survival of stage IV NSCLC due to increased use of chemotherapy.

Aarts MJ, van den Borne BE, Biesma B, Kloover JS, Aerts JG, Lemmens VE.

Int J Cancer. 2015 Mar 1;136(5):E387-95. doi: 10.1002/ijc.29216. Epub 2014 Sep 30.

10.

A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study.

Aerts JG, Codrington H, Lankheet NA, Burgers S, Biesma B, Dingemans AM, Vincent AD, Dalesio O, Groen HJ, Smit EF; NVALT Study Group.

Ann Oncol. 2013 Nov;24(11):2860-5. doi: 10.1093/annonc/mdt341. Epub 2013 Aug 28.

11.

Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer.

Schmid-Bindert G, Gebbia V, Mayer F, Arriola E, Márquez-Medina D, Syrigos K, Biesma B, Leschinger MI, Frimodt-Moller B, Ripoche V, Myrand SP, Nguyen TS, Hozak RR, Zimmermann A, Visseren-Grul C, Schuette W.

Lung Cancer. 2013 Sep;81(3):428-434. doi: 10.1016/j.lungcan.2013.05.010. Epub 2013 Jun 20.

PMID:
23790468
12.

A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation.

van Riel S, Thunnissen E, Heideman D, Smit EF, Biesma B.

Ann Oncol. 2012 Dec;23(12):3188-9. doi: 10.1093/annonc/mds525. Epub 2012 Oct 18. No abstract available.

PMID:
23079729
13.

Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands.

Verduyn SC, Biesma B, Schramel FM, van der Scheer FW, Langenfeld MK, de Peuter MA, Dingemans AM.

Health Qual Life Outcomes. 2012 Sep 10;10:108. doi: 10.1186/1477-7525-10-108.

14.

Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer.

Paz-Ares LG, Biesma B, Heigener D, von Pawel J, Eisen T, Bennouna J, Zhang L, Liao M, Sun Y, Gans S, Syrigos K, Le Marie E, Gottfried M, Vansteenkiste J, Alberola V, Strauss UP, Montegriffo E, Ong TJ, Santoro A; NSCLC [non–small-cell lung cancer] Research Experience Utilizing Sorafenib (NExUS) Investigators Study Group.

J Clin Oncol. 2012 Sep 1;30(25):3084-92. doi: 10.1200/JCO.2011.39.7646. Epub 2012 Jul 30.

PMID:
22851564
15.

Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study.

Groen HJ, Sietsma H, Vincent A, Hochstenbag MM, van Putten JW, van den Berg A, Dalesio O, Biesma B, Smit HJ, Termeer A, Hiltermann TJ, van den Borne BE, Schramel FM.

J Clin Oncol. 2011 Nov 10;29(32):4320-6. doi: 10.1200/JCO.2011.35.5214. Epub 2011 Oct 11.

PMID:
21990410
16.

Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study.

Biesma B, Wymenga AN, Vincent A, Dalesio O, Smit HJ, Stigt JA, Smit EF, van Felius CL, van Putten JW, Slaets JP, Groen HJ; Dutch Chest Physician Study Group.

Ann Oncol. 2011 Jul;22(7):1520-7. doi: 10.1093/annonc/mdq637. Epub 2011 Jan 20.

PMID:
21252061
17.

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.

Herbst RS, Sun Y, Eberhardt WE, Germonpré P, Saijo N, Zhou C, Wang J, Li L, Kabbinavar F, Ichinose Y, Qin S, Zhang L, Biesma B, Heymach JV, Langmuir P, Kennedy SJ, Tada H, Johnson BE.

Lancet Oncol. 2010 Jul;11(7):619-26. doi: 10.1016/S1470-2045(10)70132-7.

18.

Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy.

Krzakowski M, Ramlau R, Jassem J, Szczesna A, Zatloukal P, Von Pawel J, Sun X, Bennouna J, Santoro A, Biesma B, Delgado FM, Salhi Y, Vaissiere N, Hansen O, Tan EH, Quoix E, Garrido P, Douillard JY.

J Clin Oncol. 2010 May 1;28(13):2167-73. doi: 10.1200/JCO.2009.23.4146. Epub 2010 Mar 29.

PMID:
20351334
19.

A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer.

Scagliotti GV, Germonpré P, Bosquée L, Vansteenkiste J, Gervais R, Planchard D, Reck M, De Marinis F, Lee JS, Park K, Biesma B, Gans S, Ramlau R, Szczesna A, Makhson A, Manikhas G, Morgan B, Zhu Y, Chan KC, von Pawel J.

Lung Cancer. 2010 Jun;68(3):420-6. doi: 10.1016/j.lungcan.2009.07.011. Epub 2009 Aug 18.

PMID:
19692142
20.

Pneumonectomy for bronchogenic carcinoma: analysis of factors predicting short- and long-term outcome.

Veen EJ, Janssen-Heijnen ML, Ritchie ED, Biesma B, van den Bogart MP, Bolhuis RJ.

Interact Cardiovasc Thorac Surg. 2009 Aug;9(2):260-4. doi: 10.1510/icvts.2008.194456. Epub 2009 May 14.

PMID:
19443491
21.

Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.

Smit EF, Burgers SA, Biesma B, Smit HJ, Eppinga P, Dingemans AM, Joerger M, Schellens JH, Vincent A, van Zandwijk N, Groen HJ.

J Clin Oncol. 2009 Apr 20;27(12):2038-45. doi: 10.1200/JCO.2008.19.1650. Epub 2009 Mar 23.

PMID:
19307503
22.

Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status.

Goss G, Ferry D, Wierzbicki R, Laurie SA, Thompson J, Biesma B, Hirsch FR, Varella-Garcia M, Duffield E, Ataman OU, Zarenda M, Armour AA.

J Clin Oncol. 2009 May 1;27(13):2253-60. doi: 10.1200/JCO.2008.18.4408. Epub 2009 Mar 16.

23.

Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in The Netherlands.

Pompen M, Gok M, Novák A, van Wuijtswinkel R, Biesma B, Schramel F, Stigt J, Smit H, Postmus P.

Lung Cancer. 2009 Apr;64(1):110-6. doi: 10.1016/j.lungcan.2008.07.009. Epub 2008 Sep 21.

PMID:
18805601
24.

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D.

J Clin Oncol. 2008 Jul 20;26(21):3543-51. doi: 10.1200/JCO.2007.15.0375. Epub 2008 May 27.

PMID:
18506025
25.

COPD in cancer patients: higher prevalence in the elderly, a different treatment strategy in case of primary tumours above the diaphragm, and a worse overall survival in the elderly patient.

van de Schans SA, Janssen-Heijnen ML, Biesma B, Smeenk FW, van de Poll-Franse LV, Seynaeve C, Coebergh JW.

Eur J Cancer. 2007 Oct;43(15):2194-202. Epub 2007 Sep 19.

PMID:
17884463
26.

Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer.

de Jong WK, Groen HJ, Koolen MG, Biesma B, Willems LN, Kwa HB, van Bochove A, van Tinteren H, Smit EF.

Eur J Cancer. 2007 Nov;43(16):2345-50. Epub 2007 Sep 10.

PMID:
17826977
27.

Pulmonary resection for metastases from colorectal cancer.

van Schaik PM, Kouwenhoven EA, Bolhuis RJ, Biesma B, Bosscha K.

J Thorac Oncol. 2007 Jul;2(7):652-6.

28.

Anaemia management with epoetin alfa in lung cancer patients in The Netherlands.

Biesma B, van de Werf PR, Melissant CF, Brok RG.

Lung Cancer. 2007 Oct;58(1):104-11. Epub 2007 Jun 29.

PMID:
17601632
29.

Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.

van Meerbeeck JP, Kramer GW, Van Schil PE, Legrand C, Smit EF, Schramel F, Tjan-Heijnen VC, Biesma B, Debruyne C, van Zandwijk N, Splinter TA, Giaccone G; European Organisation for Research and Treatment of Cancer-Lung Cancer Group.

J Natl Cancer Inst. 2007 Mar 21;99(6):442-50.

PMID:
17374834
30.

Negligible influence of comorbidity on prognosis of patients with small cell lung cancer: a population-based study in the Netherlands.

Janssen-Heijnen ML, Lemmens VE, van den Borne BE, Biesma B, Oei SB, Coebergh JW.

Crit Rev Oncol Hematol. 2007 May;62(2):172-8. Epub 2007 Jan 2.

PMID:
17197191
31.

Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975.

Efficace F, Bottomley A, Smit EF, Lianes P, Legrand C, Debruyne C, Schramel F, Smit HJ, Gaafar R, Biesma B, Manegold C, Coens C, Giaccone G, Van Meerbeeck J; EORTC Lung Cancer Group and Quality of Life Unit.

Ann Oncol. 2006 Nov;17(11):1698-704. Epub 2006 Sep 12.

PMID:
16968876
32.
33.

Quality assurance of thoracic radiotherapy in EORTC 08941: a randomised trial of surgery versus thoracic radiotherapy in patients with stage IIIA non-small-cell lung cancer (NSCLC) after response to induction chemotherapy.

Kramer GW, Legrand CL, van Schil P, Uitterhoeve L, Smit EF, Schramel F, Biesma B, Tjan-Heijnen V, van Zandwijk N, Splinter T, Giaccone G, van Meerbeeck JP; EORTC-Lung Cancer Group.

Eur J Cancer. 2006 Jul;42(10):1391-8.

PMID:
16785054
34.

Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European organization for research and treatment of cancer (EORTC 08984).

Biesma B, Manegold C, Smit HJ, Willems L, Legrand C, Passioukov A, van Meerbeeck JP, Giaccone G; EORTC Lung Cancer Group.

Eur J Cancer. 2006 Jul;42(10):1399-406. Epub 2006 Jun 8.

PMID:
16759850
35.

Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer.

Timmer-Bonte JN, Adang EM, Smit HJ, Biesma B, Wilschut FA, Bootsma GP, de Boo TM, Tjan-Heijnen VC.

J Clin Oncol. 2006 Jul 1;24(19):2991-7. Epub 2006 May 8.

PMID:
16682725
36.

Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.

Hoekstra CJ, Stroobants SG, Smit EF, Vansteenkiste J, van Tinteren H, Postmus PE, Golding RP, Biesma B, Schramel FJ, van Zandwijk N, Lammertsma AA, Hoekstra OS.

J Clin Oncol. 2005 Nov 20;23(33):8362-70.

PMID:
16293866
37.

Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.

Timmer-Bonte JN, de Boo TM, Smit HJ, Biesma B, Wilschut FA, Cheragwandi SA, Termeer A, Hensing CA, Akkermans J, Adang EM, Bootsma GP, Tjan-Heijnen VC.

J Clin Oncol. 2005 Nov 1;23(31):7974-84.

PMID:
16258098
38.

A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment.

Wachters FM, Groen HJ, Biesma B, Schramel FM, Postmus PE, Stigt JA, Smit EF.

Br J Cancer. 2005 Jan 17;92(1):15-20.

39.

Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.

Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F, Smit H, Gaafar R, Biesma B, Manegold C, Neymark N, Giaccone G; European Organization for Research and Treatment of Cancer Lung Cancer Group.

J Clin Oncol. 2003 Nov 1;21(21):3909-17.

PMID:
14581415
40.

Carboplatin and paclitaxol (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer. an EORTC phase II study (EORTC 08958).

O'Brien ME, Splinter T, Smit EF, Biesma B, Krzakowski M, Tjan-Heijnen VC, Van Bochove A, Stigt J, Smid-Geirnaerdt MJ, Debruyne C, Legrand C, Giaccone G; EORTC Lung Cancer Group.

Eur J Cancer. 2003 Jul;39(10):1416-22.

PMID:
12826045
41.

The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment.

Hoekstra CJ, Stroobants SG, Hoekstra OS, Vansteenkiste J, Biesma B, Schramel FJ, van Zandwijk N, van Tinteren H, Smit EF.

Lung Cancer. 2003 Feb;39(2):151-7.

PMID:
12581567
42.

Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923).

Tjan-Heijnen VC, Caleo S, Postmus PE, Ardizzoni A, Burghouts JT, Buccholz E, Biesma B, Gorlia T, Crott R, Giaccone G, Debruyne C, Manegold C; European Organisation for Research Treatment of Cancer-Lung Cancer Group and Health Economics Unit.

Ann Oncol. 2003 Feb;14(2):248-57.

PMID:
12562652
43.

Recombinant human interleukin-3 administered concomitantly with chemotherapy in patients with relapsed small cell lung cancer.

Biesma B, van Kralingen KW, van Leen RW, Koster MC, Postmus PE.

J Exp Ther Oncol. 2002 Jan-Feb;2(1):47-52.

PMID:
12415620
44.

Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923.

Ardizzoni A, Tjan-Heijnen VC, Postmus PE, Buchholz E, Biesma B, Karnicka-Mlodkowska H, Dziadziuszko R, Burghouts J, Van Meerbeeck JP, Gans S, Legrand C, Debruyne C, Giaccone G, Manegold C; European Organization for Research and Treatment of Cancer-Lung Cancer Group.

J Clin Oncol. 2002 Oct 1;20(19):3947-55.

PMID:
12351591
45.

Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study.

Tjan-Heijnen VC, Postmus PE, Ardizzoni A, Manegold CH, Burghouts J, van Meerbeeck J, Gans S, Mollers M, Buchholz E, Biesma B, Legrand C, Debruyne C, Giaccone G; European Organisation for Research and Treatment of Cancer-Lung Cancer Group.

Ann Oncol. 2001 Oct;12(10):1359-68.

PMID:
11762805
46.

Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy.

Huisman C, Biesma B, Postmus PE, Giaccone G, Schramel FM, Smit EF.

Br J Cancer. 2001 Nov 16;85(10):1456-61.

48.

Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule.

Groen HJ, Fokkema E, Biesma B, Kwa B, van Putten JW, Postmus PE, Smit EF.

J Clin Oncol. 1999 Mar;17(3):927-32.

PMID:
10071286
49.

Enhanced myelotoxicity due to granulocyte colony-stimulating factor administration until 48 hours before the next chemotherapy course in patients with small-cell lung carcinoma.

Tjan-Heijnen VC, Biesma B, Festen J, Splinter TA, Cox A, Wagener DJ, Postmus PE.

J Clin Oncol. 1998 Aug;16(8):2708-14. Erratum in: J Clin Oncol 1999 Mar;17(3):1091.

PMID:
9704721
50.

A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer.

Smit EF, Fokkema E, Biesma B, Groen HJ, Snoek W, Postmus PE.

Br J Cancer. 1998;77(2):347-51.

Supplemental Content

Loading ...
Support Center